Ownership and insider activity for BioXcel Therapeutics, Inc. (BTAI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology.
Price
| Price | $0.07 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $887000 | $42.6M | $32.4M | $213.1M | $233.0M | $193.7M | $65.2M | $29.9M | $28.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $115000 | 0 | 0 | 0 | $248000 | $71000 | $131000 | $233000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | $2.0M | $2.0M | $679000 | $722000 |
| Total Current Assets | $2000 | $890000 | $43.2M | $34.1M | $217.1M | $236.8M | $202.9M | $72.1M | $37.4M | $44.7M |
| Property, Plant & Equipment | $5000 | $4000 | $327000 | $2.2M | $2.8M | $2.5M | $2.1M | $1.5M | $857000 | $231000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $7000 | $1.4M | $43.5M | $36.4M | $219.9M | $239.4M | $205.9M | $73.7M | $38.3M | $44.9M |
| Accounts Payable | $279000 | $444000 | $1.6M | $5.0M | $4.0M | $4.7M | $10.2M | $13.7M | $16.0M | $14.7M |
| Short-term Debt | 0 | $371000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $24.9M |
| Total Current Liabilities | $331000 | $2.3M | $4.7M | $8.5M | $11.8M | $16.7M | $32.9M | $27.3M | $22.2M | $53.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $93.1M | $100.6M | $102.5M | $84.7M |
| Total Liabilities | $331000 | $2.3M | $4.7M | $9.5M | $13.2M | $17.8M | $129.1M | $130.2M | $131.4M | $140.4M |
| Retained Earnings | 0 | -$4.5M | -$23.7M | -$56.7M | -$138.9M | -$245.8M | -$411.5M | -$590.6M | -$650.2M | -$720.1M |
| Total Equity | -$324000 | -$982000 | $38.9M | $26.9M | $206.7M | $221.7M | $76.8M | -$56.5M | -$93.1M | -$95.5M |
| Total Debt | 0 | $371000 | 0 | $1.0M | $1.6M | $1.4M | $94.2M | $101.4M | $102.9M | $109.7M |
| Net Debt | 0 | -$516000 | -$42.6M | -$31.4M | -$211.5M | -$231.6M | -$99.6M | $36.2M | $73.1M | $81.2M |
| Working Capital | -$329000 | -$1.4M | $38.5M | $25.6M | $205.2M | $220.1M | $170.0M | $44.9M | $15.2M | -$9.2M |
Financial Health
| Debt / Equity | -0.90 |
| Current Ratio | 0.21 |
Profitability
| Return on Equity | 69.92% |
| Return on Invested Capital | 1144.58% |
| Return on Assets | -246.05% |
| Gross Margin | 45.28% |
| Operating Margin | -6014.42% |
| Net Margin | -9549.87% |
Related companies: ANVS · BCAB · CELU · EVAX · GBIO · MAIA · MURA
Explore sector: Healthcare · Biotechnology
More sections of BTAI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks